Showing results (241-250 of 313) with videos related to
Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemiaWilliam Wierda, Susan O'Brien, Sijin Wen, et al.American Journal of Hematology|July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemiaGautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.Blood|June 7, 2003
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaHagop Kantarjian, Varsha Gandhi, Jorge Cortes, et al.Blood|August 27, 2005
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemiaStefan Faderl, Kim-Anh Do, Marcella M Johnson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemiaGail J Roboz, Francis J Giles, Ellen K Ritchie, et al.Cancer|March 27, 2015
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemiaTapan M Kadia, Stefan Faderl, Farhad Ravandi, et al.Leukemia Research|August 19, 2003
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phaseFrancis J Giles, Eric J Feldman, Gail J Roboz, et al.American Journal of Hematology|March 21, 2013
Prognostic impact of RAS mutations in patients with myelodysplastic syndromeAref Al-Kali, Alfonso Quintás-Cardama, Raja Luthra, et al.American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.Pageof 32